MOLP-2Homo sapiens (Human)Cancer cell line

Also known as: MOLP2

🤖 AI SummaryBased on 7 publications

Quick Overview

Human B-cell line for multiple myeloma research

Detailed Summary

MOLP-2 is a human B-cell line derived from multiple myeloma patients, widely used in cancer research. It exhibits characteristics of plasma cells, including expression of specific surface markers and genetic abnormalities associated with myeloma. This cell line is valuable for studying the molecular mechanisms of myeloma and testing therapeutic strategies. Research on MOLP-2 has contributed to understanding the genetic and functional aspects of multiple myeloma, including drug resistance and tumor biology.

Research Applications

Multiple myeloma researchDrug resistance studiesTumor biology investigations

Key Characteristics

B-cell originPlasma cell markersGenetic abnormalities associated with myeloma

Generated on 6/18/2025

Basic Information

Database ID	CVCL_2123
Species	Homo sapiens (Human)
Tissue Source	Peripheral blood[UBERON:UBERON_0000178]

Donor Information

Age	55
Age Category	Adult
Sex	Male

Disease Information

Disease	Multiple myeloma
Lineage	Lymphoid
Subtype	Plasma Cell Myeloma
OncoTree Code	PCM

DepMap Information

Source Type	DSMZ
Source ID	ACH-000453_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ala159Val (c.476C>T)	Homozygous	-	Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

8,9

D16S539

D18S51

D19S433

13,14

D21S11

D2S1338

18,19

D3S1358

16,17

D5S818

D7S820

11,12

D8S1179

13,15

FGA

Penta D

9,10

Penta E

TH01

TPOX

10,11

vWA

16,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.

Sirota M., Wiita A.P.

Leukemia 34:2754-2765(2020).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Taniwaki M., Inazawa J.

Am. J. Pathol. 165:71-81(2004).

DOI PubMed PMC

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Drexler H.G., Matsuo Y.

Leuk. Res. 24:681-703(2000).

DOI PubMed

Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor.

Matsuo Y., Nakamura S., Adachi T., Tsubota T.

Hum. Cell 6:310-313(1993).

PubMed

Web Resources

keatslab.org